AnaptysBio (NASDAQ:ANAB) Stock Price Up 8.2%

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report)'s share price rose 8.2% on Friday . The stock traded as high as $20.52 and last traded at $20.42. Approximately 253,023 shares were traded during trading, a decline of 19% from the average daily volume of 312,846 shares. The stock had previously closed at $18.87.

Analyst Ratings Changes

A number of brokerages have issued reports on ANAB. Stifel Nicolaus began coverage on AnaptysBio in a research report on Wednesday, February 21st. They issued a "buy" rating and a $50.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on shares of AnaptysBio from $30.00 to $28.00 and set a "neutral" rating for the company in a research note on Monday, April 1st. Piper Sandler began coverage on shares of AnaptysBio in a research note on Friday, February 16th. They issued an "overweight" rating and a $80.00 price objective for the company. Leerink Partnrs reiterated an "outperform" rating on shares of AnaptysBio in a research note on Tuesday, April 16th. Finally, Wells Fargo & Company began coverage on shares of AnaptysBio in a research note on Thursday, April 11th. They set an "overweight" rating and a $56.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $46.22.

AnaptysBio Stock Performance

The stock has a market cap of $561.96 million, a price-to-earnings ratio of -3.41 and a beta of -0.30. The business's fifty day simple moving average is $22.99 and its 200 day simple moving average is $20.57.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. The business had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. As a group, analysts forecast that AnaptysBio, Inc. will post -6.17 EPS for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In other news, insider Eric J. Loumeau sold 5,000 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the insider now owns 3,240 shares in the company, valued at approximately $81,000. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other AnaptysBio news, CEO Daniel Faga sold 145,940 shares of the firm's stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $22.78, for a total value of $3,324,513.20. Following the completion of the sale, the chief executive officer now owns 752,087 shares in the company, valued at approximately $17,132,541.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric J. Loumeau sold 5,000 shares of the firm's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the insider now owns 3,240 shares of the company's stock, valued at approximately $81,000. The disclosure for this sale can be found here. In the last quarter, insiders have sold 157,005 shares of company stock worth $3,586,199. 35.50% of the stock is currently owned by company insiders.

Institutional Trading of AnaptysBio

A number of institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC acquired a new position in AnaptysBio during the first quarter worth $38,000. China Universal Asset Management Co. Ltd. lifted its position in AnaptysBio by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company's stock worth $66,000 after purchasing an additional 2,390 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of AnaptysBio by 134.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company's stock worth $106,000 after acquiring an additional 3,381 shares during the last quarter. Quest Partners LLC bought a new position in AnaptysBio in the 4th quarter valued at approximately $119,000. Finally, SG Americas Securities LLC acquired a new stake in AnaptysBio during the 4th quarter valued at approximately $126,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.